title: Cytokines inhibit sexual behavior in female rats: II. Prostaglandins mediate the suppressive effects of interleukin-1beta.
abstract: The proinflammatory cytokine interleukin-1 (IL-1) induces several behavioral alterations that are characteristic of illness, such as anorexia and reduced locomotor and social activity. We have recently demonstrated that IL-1 inhibits sexual activity, motivation and attractivity in female, but not in male rats following either central or peripheral administration. In the present study we examined the involvement of prostaglandin (PG) synthesis in mediating IL-1-induced suppression of female sexual behavior. Administration of the cyclooxygenase blockers indomethacin or ibuprofen completely prevented IL-1-induced suppression of female sexual behavior, including the reduction in proceptive behavior, the lordosis response to a male's mounts, and the preference for a sexually active partner. In a subsequent study, ex-vivo release of hypothalamic PGE2 and the secretion of corticosterone (CS) were measured in males and estrous females following IL-1 administration. At the same time and dose of IL-1 administration that significantly reduced sexual behavior in female but not male rats, IL-1 produced a significant increase in PGE2 release in female, but not in male rats. In contrast, IL-1 induced a significant elevation of serum CS levels in males but not in females. These findings suggest that PG synthesis is involved in mediating the effects of IL-1 on female sexual behavior. Furthermore, differential secretion of PGs and CS may underlie the gender difference in the effects of IL-1 on sexual behavior.
authors.affiliation: Department of Psychology, The Hebrew University of Jerusalem, Mount Scopus, Jerusalem, 91905, Israel.
authors.forename: R
authors.initials: R
authors.lastname: Avitsur
authors.forename: J
authors.initials: J
authors.lastname: Weidenfeld
authors.forename: R
authors.initials: R
authors.lastname: Yirmiya
mesh_terms: D000818:Animals; D003345:Corticosterone / Q000378:metabolism; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D016207:Cytokines / Q000494:pharmacology*; D003864:Depression, Chemical; D005260:Female; D007031:Hypothalamus / Q000378:metabolism / Q000502:physiology; D007052:Ibuprofen / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology; D007276:Injections, Intraventricular; D007375:Interleukin-1 / Q000494:pharmacology*; D008297:Male; D010431:Pentoxifylline / Q000494:pharmacology; D011187:Posture; D011453:Prostaglandins / Q000378:metabolism / Q000502:physiology*; D051381:Rats; D011916:Rats, Inbred F344; D012726:Sexual Behavior, Animal / Q000187:drug effects*; D014665:Vasodilator Agents / Q000494:pharmacology
chemical_list: D016861:Cyclooxygenase Inhibitors; D016207:Cytokines; D007375:Interleukin-1; D011453:Prostaglandins; D014665:Vasodilator Agents; D010431:Pentoxifylline; D003345:Corticosterone; D007052:Ibuprofen; D007213:Indomethacin